Medical contributors to psychiatric symptoms are routinely missed at intake. Here’s the biological workup that changes what treatment-resistant looks like.
A patient comes in with persistent depression. They’ve tried two antidepressants. Neither worked particularly well. Their previous provider documented “treatment-resistant depression” and increased the dose.
You order labs.
TSH is borderline. Ferritin is 14. Vitamin D is 19. Homocysteine is elevated.
This isn’t a psychiatric case that failed medication. It’s a biological picture that was never fully evaluated.
Scenarios like this are why a growing number of psychiatric nurse practitioners, psychiatrists, and mental health providers are building a comprehensive medical workup into their intake process — not as an alternative to psychiatric treatment, but as the biological foundation it should rest on.
A biological workup does not replace psychiatric diagnosis or psychotherapy. It improves diagnostic clarity by identifying medical contributors that meaningfully affect psychiatric symptoms and treatment response.
Here is the panel that’s emerging as the standard in biologically informed psychiatric practice, and the clinical rationale behind each test.
At a Glance
- Thyroid dysfunction, nutrient deficiencies, inflammation, and hormonal imbalances can produce symptoms clinically indistinguishable from depression, anxiety, ADHD, and bipolar disorder
- Standard psychiatric intake rarely screens for medical contributors beyond a basic metabolic panel
- A targeted biological workup adds clarity to cases that appear treatment-resistant
- The value of these biomarkers compounds when tracked longitudinally rather than interpreted as isolated snapshots
- Tracking multiple biomarkers across patients requires a system, not a spreadsheet
The Core Panel at a Glance
| Category | Recommended Tests |
|---|---|
| Thyroid | TSH, Free T3, Free T4, TPO Antibodies, Thyroglobulin Antibodies |
| Iron Status | Ferritin, serum iron, TIBC, transferrin saturation |
| Nutrients | Vitamin D (25-OH), B12, Folate (RBC), Homocysteine, Magnesium (RBC), Zinc |
| Inflammation | hs-CRP, Homocysteine |
| Metabolic | Fasting glucose, HbA1c, fasting insulin |
| Hormones | Testosterone (total/free), Estradiol, Progesterone, DHEA-S |
| General Health | CMP, CBC with differential |
Clinical rationale for each test is detailed in the sections below.
Why a Biological Workup Belongs at Intake
Traditional psychiatric training focuses on symptom patterns, diagnostic criteria, and medication response. What it rarely teaches is that many of the most common psychiatric presentations have identifiable medical contributors that precede, mimic, or worsen the condition — and that no antidepressant, anxiolytic, or stimulant addresses.
Major journals including JAMA Psychiatry have in recent years called for integrating biological information into psychiatric assessment. The evidence base for medical contributors to psychiatric symptoms — thyroid dysfunction, iron deficiency, inflammatory states, hormonal imbalances, metabolic dysregulation — is not fringe. It’s established medicine that psychiatry has been slow to operationalise at intake.
The question isn’t whether to test. It’s which tests yield the highest clinical return, and how to interpret them in the context of the psychiatric presentation.
The Core Panel
1. Thyroid — Full Panel, Not Just TSH
Tests: TSH, Free T3, Free T4, TPO Antibodies, Thyroglobulin Antibodies
Thyroid disorders are among the most well-documented medical causes of psychiatric symptoms. Multiple psychiatric and endocrine guidelines recommend thyroid evaluation during the assessment of depressive and anxiety symptoms — yet most standard workups stop at TSH alone, missing a clinically significant subset of patients.
What TSH-only misses:
- Subclinical hypothyroidism — TSH mildly elevated, Free T4 normal; associated with depression, cognitive slowing, and fatigue that responds poorly to antidepressants alone
- Hashimoto’s thyroiditis — TPO antibodies positive, sometimes with entirely normal TSH; associated with mood instability, anxiety, and cognitive symptoms even before thyroid hormone levels shift measurably
- Low Free T3 — impaired T4-to-T3 conversion; TSH and T4 can both appear normal while the metabolically active hormone is insufficient
- Lithium-related thyroid effects — long-term lithium use suppresses thyroid function; patients on lithium warrant full panel monitoring, not TSH alone
- Postpartum thyroiditis — frequently presents with anxiety and depression in the months after delivery; TPO antibodies are a key early marker
A patient with a TSH of 3.8 and positive TPO antibodies is a fundamentally different clinical picture from a patient with a TSH of 3.8 and no antibodies. The full panel tells you which one you’re treating.
2. Iron and Ferritin
Tests: Serum ferritin, serum iron, TIBC, Transferrin Saturation
Iron deficiency without anemia is one of the most commonly missed contributors to psychiatric presentations, and one of the most actionable findings when identified.
Ferritin — the storage form of iron — is the most sensitive marker for iron depletion before anemia develops. Standard reference ranges are notoriously wide; a ferritin of 14 ng/mL is technically “within range” at most labs but is functionally inadequate for many patients.
Psychiatric relevance of low ferritin:
- Associated with fatigue, irritability, poor concentration, and worsening anxiety — symptoms that frequently dominate a psychiatric presentation and are easily attributed to the primary diagnosis
- Strongly linked to restless legs syndrome, which is highly prevalent in patients with ADHD and frequently misattributed to stimulant side effects
- Associated with SSRI nonresponse — iron is a cofactor in serotonin synthesis; patients with low ferritin may have a biochemical impediment to antidepressant response that no dose adjustment addresses
- Iron deficiency without anemia is particularly common in women of reproductive age and is chronically underdiagnosed in psychiatric settings
Serum iron and TIBC provide additional context — ferritin can be falsely elevated by acute inflammation, making the full iron panel more reliable than ferritin alone when inflammatory states are suspected.
3. Vitamins and Key Nutrients
Tests: Vitamin D (25-OH), B12, Folate, Homocysteine, Magnesium, Zinc
Each of these has a distinct and well-documented psychiatric relevance:
Vitamin D — Deficiency is associated with depression, seasonal mood changes, fatigue, and cognitive symptoms. In northern latitudes, populations with limited sun exposure, and patients on certain medications (antiepileptics, glucocorticoids), low Vitamin D should be assumed until tested. The 25-OH form is the appropriate marker for assessing systemic status.
B12 and Folate — Essential for one-carbon metabolism and neurotransmitter synthesis. B12 deficiency can present as depression, cognitive decline, peripheral neuropathy, and in severe cases psychosis — and is frequently missed in patients who appear psychiatrically complex. RBC folate is a more reliable marker of tissue stores than serum folate. Elevated homocysteine is a functional indicator of B12/folate insufficiency even when serum levels appear within range, and in psychiatric patients is associated with depression, cognitive decline, and increased risk of treatment resistance.
Magnesium (RBC) — Serum magnesium is a poor indicator of intracellular status and is frequently normal even when cellular depletion is present. RBC magnesium is the more clinically meaningful marker. Magnesium is involved in neurological function and mood regulation; deficiency is associated with anxiety, irritability, and sleep disturbance.
Zinc — Low zinc has been linked to mood disorders and cognitive dysfunction, and is particularly relevant in patients with poor dietary intake or high physiological stress, as cortisol accelerates zinc depletion.
4. Inflammation Markers
Tests: hs-CRP, Homocysteine
There is now substantial evidence — including multiple published meta-analyses — that a subset of patients with major depression have an inflammatory phenotype, characterised by elevated inflammatory markers, a distinct symptom profile (prominent fatigue, psychomotor slowing, anhedonia), and differential response to standard antidepressants.
hs-CRP is the most accessible marker for this stratification. Elevated hs-CRP in a depressed patient suggests a biological subtype that may warrant a different treatment approach. Several randomised trials have examined anti-inflammatory adjuncts specifically in patients with elevated CRP; knowing this marker at intake is increasingly clinically relevant, not just academically interesting.
Decode your own result in 30 seconds
Enter your value and get a personal interpretation — what your number means in plain language, what to pair it with, and when to follow up.
Homocysteine is both a cardiovascular risk marker and a modifiable biological variable in psychiatric care. Elevated homocysteine is associated with depression and cognitive symptoms, and responds to targeted B-vitamin intervention — making it one of the most actionable findings in this panel.
5. Metabolic Markers
Tests: Fasting glucose, HbA1c, Fasting Insulin
Metabolic dysfunction is both a contributor to psychiatric symptoms and a consequence of psychiatric treatment. This makes metabolic monitoring doubly important in psychiatric practice.
As a contributor: Insulin resistance and blood sugar dysregulation are associated with mood instability, cognitive slowing, fatigue, and increased depression risk. A patient with an HbA1c of 5.8 and fasting insulin of 18 has a metabolic picture that will undermine psychiatric treatment regardless of medication optimisation.
As a treatment consequence: Second-generation antipsychotics (SGAs) — olanzapine, quetiapine, clozapine, risperidone — carry significant metabolic side effect profiles including weight gain, dyslipidaemia, and insulin resistance. Metabolic monitoring in patients on SGAs is recommended by the American Psychiatric Association and multiple international consensus guidelines. Fasting glucose, HbA1c, and a lipid panel at baseline and annually (or more frequently based on clinical picture) should be routine in this population.
This section also has direct relevance for patients with bipolar disorder, where metabolic comorbidity is highly prevalent and metabolic health significantly affects illness course and medication tolerability.
6. Sex Hormones
Tests: Testosterone (total and free), Estradiol, Progesterone, DHEA-S
Hormonal contributors to psychiatric symptoms are frequently overlooked, particularly in presentations that appear treatment-resistant.
High-yield clinical scenarios:
- Perimenopausal and menopausal women with new-onset or worsening depression, anxiety, or cognitive symptoms — estrogen and progesterone fluctuations are a primary driver that no antidepressant fully addresses
- Postpartum presentations — estrogen and progesterone drop precipitously after delivery; this is the hormonal context for postpartum depression and anxiety, and baseline hormone levels in the postpartum period can inform treatment decisions
- Men with low mood, fatigue, reduced motivation, and poor concentration — low testosterone is frequently missed in psychiatric workups and presents in ways that are easily attributed to depression
- DHEA-S — levels decline with age and chronic illness and may provide additional context in patients presenting with fatigue, low mood, and reduced resilience to stress
7. Comprehensive Metabolic Panel and CBC
Tests: Standard CMP + CBC with differential
These are ordered routinely but are worth reviewing specifically through a psychiatric lens:
- ALT/AST — liver function is relevant before initiating hepatically metabolised psychotropics and for monitoring during treatment
- Kidney function (BUN, creatinine, eGFR) — essential for lithium dosing and monitoring; also relevant for medication clearance in older patients
- CBC with differential — MCV elevation can flag B12/folate deficiency before serum levels show it; lymphocyte patterns can suggest immune dysregulation; low platelets are relevant in patients taking valproate
- Albumin — a marker of nutritional status and chronic inflammation; low albumin affects protein-bound medication levels
A Note on the Extended Panel
For patients who don’t respond as expected — particularly those carrying a treatment-resistant label — a second tier of testing can add resolution. This includes amino acid panels (relevant to neurotransmitter precursor availability), comprehensive hormone panels, and selected specialty testing based on the clinical picture.
The goal is not comprehensive testing for its own sake. It’s targeted investigation when the standard workup doesn’t explain the presentation. The core panel above answers the most common biological questions. Extended testing is for cases where it doesn’t.
Commonly Missed Lab Findings in Psychiatric Patients
Results that fall within the standard reference range but still carry clinical significance are among the most frequent missed opportunities in psychiatric practice. These are the ones that appear most often:
| Biomarker | Common “Within Range” Result | Why It Still Matters |
|---|---|---|
| Ferritin | 14 ng/mL | Associated with fatigue, restless legs, poor concentration, and SSRI nonresponse |
| Vitamin D | 22 ng/mL | Associated with low mood, fatigue, and seasonal symptom patterns |
| TSH | 3.8 mIU/L | May reflect evolving thyroid dysfunction, particularly when TPO antibodies are present |
| HbA1c | 5.8% | Indicates early insulin resistance; associated with cognitive slowing and mood instability |
| Homocysteine | 14 μmol/L | Associated with depression and cognitive decline; modifiable with B-vitamin intervention |
| Magnesium | Low-normal | Associated with anxiety, irritability, and sleep disturbance; serum levels often appear normal |
The clinical question is never simply “is this within range?” It’s “is this adequate for this patient, presenting with these symptoms?”
The Tracking Problem No One Talks About
Running a comprehensive lab panel at intake is the easy part. The harder problem is what happens to those results over time.
A patient returns in three months. Their ferritin has come up from 14 to 52. Their Vitamin D has moved from 19 to 48. Their homocysteine has dropped from 18 to 9. Their mood is meaningfully better. How do you document that trajectory in a way that’s useful — to you, to your patient, and to any other provider involved in their care?
Most practitioners end up with results scattered across lab portals, PDFs, and patient chart notes. Spreadsheets get built. Spreadsheets get abandoned. Instead of opening five separate Quest PDFs to compare ferritin trends across 18 months, the clinical picture should be visible at a glance — longitudinal biomarker graphs alongside medications, treatment changes, and uploaded reports.
That’s the operational problem HealthMatters Pro solves. Upload results from any lab — LabCorp, Quest, Genova, specialty labs — and see every patient’s biomarker history on a single timeline. Track the markers that matter most for your clinical model, share results directly with patients, and build the longitudinal record that transforms a series of snapshots into a coherent clinical story.
HealthMatters Pro is used by psychiatric nurse practitioners, integrative psychiatrists, and functional medicine clinicians to track longitudinal biomarker trends across thousands of lab reports from over 10 supported lab providers.
Explore HealthMatters Pro for practitioners →
A Note on Reference Ranges
One of the most consistent frustrations in biologically informed psychiatric practice is that standard lab reference ranges are calibrated for population averages, not clinical optimality. A ferritin of 14 ng/mL is within range. A Vitamin D of 22 ng/mL is within range. A TSH of 3.9 is within range.
None of these is adequate for a patient presenting with fatigue, low mood, and poor concentration.
Interpreting results in the context of the patient’s symptoms and clinical picture — rather than accepting “within range” as equivalent to “not a problem” — is what distinguishes a thorough biological workup from a checkbox exercise. HealthMatters allows practitioners to set customised reference ranges per patient, so the dashboard reflects clinical targets rather than population averages.
Frequently Asked Questions
Should I order all of these tests at every intake? A practical approach is a core panel at intake — thyroid, iron/ferritin, B12, folate, homocysteine, Vitamin D, hs-CRP, fasting glucose, HbA1c, CMP, CBC — with hormonal and extended testing added based on the clinical presentation. The core panel takes one blood draw and answers the most common biological questions in one visit.
How do I explain a biological workup to patients who expect a symptom-focused intake? Frame it as ruling out physical contributors before making treatment assumptions. Most patients respond positively — particularly those who’ve had prior treatment that didn’t fully work. The framing of “I want to make sure we’re not missing something medical that’s driving your symptoms” is well-received and builds trust early in the therapeutic relationship.
How often should labs be repeated? Nutrient levels that were deficient at baseline are typically rechecked at 3–4 months after intervention. Thyroid antibodies and inflammatory markers in stable patients may be checked annually. Metabolic markers in patients on SGAs warrant more frequent monitoring. The goal is purposeful retesting that tracks meaningful change, not reflexive annual panels.
What do I do when results are “within range” but the patient is symptomatic? This is where clinical interpretation diverges from lab report interpretation. A ferritin of 18 is within range and is also too low for many symptomatic patients. Knowing which markers have clinically meaningful optimal ranges — as distinct from population reference ranges — is a core skill in biologically informed practice, and one worth documenting in patient records alongside the raw values.
References
- Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. https://pubmed.ncbi.nlm.nih.gov/10767867/
- Neuropsychiatric Manifestations of Thyroid Diseases. https://pmc.ncbi.nlm.nih.gov/articles/PMC9938951/
- Association between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. https://pmc.ncbi.nlm.nih.gov/articles/PMC3680022/
- Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327519/
- Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. https://pubmed.ncbi.nlm.nih.gov/24632894/
- Metabolic monitoring among patients with psychotic disorders taking antipsychotics: results of a quality improvement project to address this challenging guideline-practice gap. https://pmc.ncbi.nlm.nih.gov/articles/PMC12336612/
- Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. https://pmc.ncbi.nlm.nih.gov/articles/PMC4095663/
This article is intended for licensed healthcare practitioners. It does not constitute clinical guidelines or replace professional judgment in individual patient care.
